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ttp://dx.doi.org/10.1016/j.ajpath.2013.03.014Clinical studies and animal experimentation have shown that colonic inﬂammation is associated with an
increased number and reactivity of platelets, coagulation abnormalities, and enhanced thrombus
formation. The objective of this study was to deﬁne the contribution of IL-6 to the thrombocytosis,
exaggerated agonist-induced platelet aggregation, and enhanced extra-intestinal thrombosis that occur
during experimental colitis. The number of mature and immature platelets, platelet life span, thrombin-
induced platelet aggregation response, and light/dye-induced thrombus formation in cremaster muscle
arterioles were measured in wild-type (WT) and IL-6edeﬁcient (IL-6/) mice with dextran sodium
sulfate (DSS)-induced colitis. DSS colitis in WT mice was associated with thrombocytosis with an elevated
number of both mature and immature platelets and no change in platelet life span. The thrombocytosis
response was absent in IL-6/ mice. DSS treatment also enhanced the platelet aggregation response to
thrombin and accelerated thrombus development in WT mice, but not in IL-6/ mice. Exogenous IL-6
administered to WT mice elicited a dose-dependent enhancement of thrombus formation. These ﬁnd-
ings indicate that IL-6 mediates the thrombocytosis, platelet hyperreactivity, and accelerated thrombus
development associated with experimental colitis. The IL-6edependent colitis-induced thrombocytosis
appears to result from an enhancement of thrombopoiesis because platelet life span is unchanged.
(Am J Pathol 2013, 183: 173e181; http://dx.doi.org/10.1016/j.ajpath.2013.03.014)Supported by the National Institute of Diabetes and Digestive and
Kidney Diseases grant P01 DK43785-20.
E.Y.S. and S.K. contributed equally to this work.Inﬂammatory bowel diseases (IBDs) are associated with an
increased risk of thrombus formation both within the
inﬂamed bowel and in extra-intestinal tissues, such as lung
and skeletal muscles.1,2 The accelerated thrombus develop-
ment during colonic inﬂammation is evidenced in large
arteries and veins, as well as in the microvasculature.2,3 The
prothrombogenic phenotype in IBD is often accompanied by
increases in the blood count (reactive thrombocytosis)4 and
reactivity of platelets3 and by an imbalance between pro-
coagulant and anticoagulant mechanisms.3 Although a 50%
to 100% increase in blood platelet count is commonly re-
ported for patients with active IBD5e7 and the association of
thrombocytosis with active IBD has led to the proposal that
platelet count is a useful marker of disease activity,8 it
remains unclear whether the elevated platelet count is
mechanistically linked to the enhanced platelet reactivity and
accelerated thrombus development in IBD. Such a link
appears tenable because accelerated thrombopoiesis wouldstigative Pathology.
.result in an increased percentage of circulating platelets that
are young and more hemostatically active than older
platelets.9,10
Enhanced thrombus formation and the other extra-intestinal
manifestations (eg, platelet abnormalities, inﬂammation of
eyes, joints, liver) of IBD2,11 suggest that cellular (eg, activated
leukocytes or platelets) and/or chemical signals are liberated
from the inﬂamed bowel to elicit these responses in distant
vascular beds and hematopoietic tissue. Several pro-
inﬂammatory cytokines [eg, IL-1b, tumor necrosis factor-a
(TNF-a), IL-6] produced and released by the inﬂamed colon in
human and experimental IBD12,13 have been shown to target
components of the coagulation cascade and to alter platelet
function in a manner that would predispose the vasculature to
Senchenkova et althrombus development.14e16 Of the cytokines studied to date,
only IL-6 exhibits the ability to mediate all of the platelet
responses that are characteristic of colonic inﬂammation, that
is, thrombocytosis,17 platelet hyperreactivity,18,19 and accel-
erated thrombus formation.20 For example, animals treated
with IL-6 exhibit an increased platelet count, and the platelets
are more sensitive to activation by thrombin and other
platelet agonists.18 IL-6 has been shown to act directly on
megakaryocytes to increase platelet production,18 and it acts
on hepatocytes to increase the production and release of
thrombopoietin (TPO), a potent stimulant of platelet produc-
tion.6 Although IL-6 has been implicated in the thrombocy-
tosis of IBD on the basis of clinical reports that describe an
association between the elevated plasma concentrations of
TPO and IL-6 with blood platelet count,6 the contribution of
IL-6 to colitis-induced thrombocytosis has not been directly
addressed in either the clinical or experimental setting.
The overall aim of this study was to assess the contri-
bution of IL-6 to the platelet abnormalities and accelerated
extra-intestinal thrombosis that are observed in a murine
model of colonic inﬂammation. We evaluated the role of
IL-6 in mediating the increased platelet count, whether IL-6
is responsible for the appearance of immature platelets, and
if the life span of platelets is altered in an IL-6edependent
manner in experimental IBD. The role of IL-6 in colitis-
induced platelet hyperreactivity to thrombin was also
examined as well as the contribution of membrane-bound
and soluble IL-6 receptors to thrombin-mediated aggrega-
tion of platelets from colitic mice. Finally, the contribution
of IL-6 to colitis-enhanced extra-intestinal thrombosis was
evaluated with immunoblockade or genetic deﬁciency of
IL-6. Our ﬁndings indicate that IL-6 plays a major role in
the enhanced production of highly reactive platelets and
accelerated thrombus development in extra-intestinal tissue
during colonic inﬂammation.
Materials and Methods
Animals
Male C57BL/6J mice and IL-6edeﬁcient (IL-6/) mice
(B6.129S6-Il6tm1Kopf, C57BL/6J background) were purchased
from The Jackson Laboratory (Bar Harbor, ME). The mice
were housed under speciﬁc pathogen-free conditions in stan-
dard cages and fed standard laboratory chow and water until
the desired age (6 to 8 weeks). All animal procedures were
reviewed and approved by the Institutional Animal Care and
Use Committee of Louisiana State University Health Sciences
Center and were performed according to the criteria outlined
by the National Institutes of Health.
Acute Colitis Model
Acute colitis was induced with 3% dextran sodium sulfate
(DSS; 40,000 molecular weight; MP Biomedicals, Solon,
OH) dissolved in ﬁlter-puriﬁed drinking water for 7 days, as174previously described.14,21 Control mice received regular
drinking water without DSS.
Histology
Histological examination was performed on samples of
distal colon, which were ﬁxed in 10% formalin before
embedding in parafﬁn and staining with hematoxylin and
eosin. The histological examination was performed in
a blinded manner (S.Z.) with the use of a previously vali-
dated scoring system,22 in which severity of inﬂammation (0
to 3 scale), depth of injury (0 to 3 scale), and crypt damage
(0 to 4 scale) are multiplied by an integer from 1 through 4,
representing the percentage of involvement of the colonic
wall (1, 0% to 25%; 2, 26% to 50%; 3, 51% to 75%; 4, 76%
to 100%), for a maximum possible score of 40.
In Vivo Biotinylation Method for Platelet Life Span
Measurement
Flow cytometry was used to quantify the relative numbers
and life spans of mature and immature platelets in blood of
control mice and colitic mice. The in vivo biotinylation
method of Ault et al9 was used to measure platelet life span.
After intravenous administration (1.2 mg dissolved in 300
mL of saline), biotin (Sulfo-NHS-LC-biotin; ProteoChem,
Denver, CO) covalently binds to free amino groups on the
surface of all blood cells. Biotin-positive cells were detected
in tail vein blood samples (10 to 15 mL, drawn daily over
5 days) with the use of ﬂow cytometry by binding with
streptavidin conjugated with phycoerythrin (eBioscience,
San Diego, CA). Platelets were distinguished from other
biotin-positive blood cells by staining with CD41-
allophycocyanin (isotype control rat IgG1, k; eBioscience).
Newly released (immature) platelets are biotin negative,
whereas mature platelets remain biotin positive for the
remainder of their life span. Hence, the entire platelet pop-
ulation becomes biotin negative as the platelet population
ages. Young reticulated platelets were identiﬁed by staining
with thiazole orange (TO; Sigma-Aldrich, St. Louis, MO),
which binds to nucleic acids (DNA and RNA). Fresh blood
samples were incubated with 1 mg/mL TO (dissolved in
PBS) for 15 minutes at room temperature.23 Formaldehyde
(1%; Polyscience Inc., Warrington, PA) was used for cell
ﬁxation. An analysis of the staining pattern of platelets
(CD41þ) (detected over several days after TO and biotin
administration) for TOþ and streptavidin-phycoerythrinþ
was used to show the numbers and life spans of both mature
and immature platelets, as previously described.9,24 The
three-color analysis was performed on an LSRII ﬂow
cytometer (BD Biosciences, San Jose, CA) and analyzed
with FACSDiva software version 6.1.3 (BD Biosciences),
with the gate set around CD41-allophycocyaninþ cells, and
10,000 to 20,000 events were collected. The absolute blood
platelet count was determined manually with the use of
a hemocytometer. Platelet life span and immature and matureajp.amjpathol.org - The American Journal of Pathology
IL-6 and Colitis-Induced Thrombosisplatelet counts were determined in the following groups
of mice: i) WT-control (n Z 5), ii) WT-DSS (n Z 7), iii)
IL-6/-DSS (nZ 5), and iv) IL-6/ bone marrow chimera
(IL-6/0WT) chimera-DSS (n Z 5).Platelet Aggregation
Arterial blood from control and colitic mice was drawn into
a syringe that contained acid citrate dextrose with 1 mmol/L
EDTA and apyrase (grade VII; Sigma-Aldrich). Sample
processing was started immediately after blood collection.
Aggregation was induced with thrombin 0.63 U/mL (EC50),
and platelet aggregation velocity was measured as previously
described.14,25,26 Platelet aggregation velocity was measured
from platelet-rich plasma derived from the following groups
of mice: i) WT-control (n Z 7), ii) WT-DSS (n Z 7), iii)
IL-6/-DSS mice (nZ 7), iv) IL-6/0WT chimera-DSS
(n Z 6), v) WT-DSS mice treated with a rat antieIL-6ra
(CD126) blocking antibody (Angio-Proteomic, Boston, MA;
100 mg/mouse in 0.2 mL of normal saline administered 24
hour before the experiment; nZ 5), and vi) WT-DSS mice
treated with an anti-gp130 blocking antibody (R&D System
Inc., Minneapolis, MN; 20 mg/mouse in 0.2 normal saline
administered 24 hours before the experiment; nZ 6).Intravital Microscopy and Light/Dye-Induced
Thrombosis
The mouse cremaster muscle was prepared for microscopic
observation as previously described.14,27 Light and ﬂuorescent
microscopic images from an upright microscope (BX51WI;
Olympus, Tokyo, Japan) with a 40 water immersion
objective lens (LUMPlan FI/IR 40/0.80; Olympus) were
projected onto a monitor (Trinitron PVM-2030; Sony, Tokyo,
Japan) through a color video camera (VK-C150; Hitachi,
Tokyo, Japan) or a charge-coupled device video camera (XC-
77; Hamamatsu, Hamamatsu City, Japan), respectively. The
images were recorded with a DVD recorder (SR-MV50; JVC,
Wayne, NJ). A video timer (Time-Date Generator WJ-810;
Panasonic, Osaka, Japan) was connected to the monitor to
record time and date. The diameters of the selected cremaster
muscle microvessels were measured by video analysis soft-
ware (ImageJ software version 1.37; NIH, Bethesda, MD) on
a personal computer (G4 Macintosh; Apple, Cupertino City,
CA). Fluorescein isothiocyanate-dextran (5%) 10 mL/kg
(150,000 molecular weight; Sigma Chemicals, St. Louis, MO)
was infused via a cannulated jugular vein. Photoactivation of
ﬂuorescein isothiocyanate-dextran (excitation, 495 nm; emis-
sion, 519 nm) within the selected microvessels was achieved
by epi-illumination with a 175-W xenon lamp (Lambda LS,
Sutter, CA) and a ﬂuorescein ﬁlter cube (HQ-FITC; Chroma
Technology, Bellows Falls, VT). The excitation power density
was measured daily (ILT 1700 Radiometer, SED033 detector;
International Light Technologies, Peabody, MA) and main-
tained within 1% of 0.77 W/cm2, as previously described.27,28The American Journal of Pathology - ajp.amjpathol.orgSecond- or third-order arterioles with a diameter of 30 to
50 mm, a minimum length of 100 mm, and a wall shear
rate >500/s were randomly selected in the mouse cremaster
muscle to study thrombus formation. Epi-illumination was
continuously applied to the vessels, and thrombus formation
was quantiﬁed by determining the time of onset of platelet
deposition/aggregation (onset time) and the time required for
complete cessation for >60 seconds (cessation time). Epi-
illumination was discontinued once blood ﬂow ceased in the
vessel under study. The results from each arteriole were
averaged from two to three thrombi produced in each mouse.
The light/dye method was used to monitor thrombus
formation in the following experimental groups: i) control WT
mice receiving an intrascrotal injection of 0.2 mL of saline at 5
hours before vessel photoactivation (n Z 7); ii) control WT
mice injected intrascrotally with recombinant mouse IL-6
(R&D Systems, Minneapolis, MN) at a concentration of
either 10 (nZ 5), 100 (nZ 5), or 500 ng (nZ 5) per mouse
(dissolved in 0.2 mL of normal saline) at 5 hours before
photoactivation; iii) WT mice on water (n Z 10); iv) DSS-
treated WT mice (WT-DSS) (n Z 10); v) antieIL-6 anti-
body (BD Biosciences) treated (100 mg/mouse administered
24 hours before photoactivation) WT-DSS mice (nZ 8); and
iv) DSS-treated IL-6/ mice (nZ 9).
Production of Bone Marrow Chimeras
In some mice, bone marrow from IL-6/ donor mice was
transplanted into WT recipients to produce IL-6/0WT
chimeras, wherein only circulating blood cells are IL-6
deﬁcient. IL-6edeﬁcient BM cells (5  106) were trans-
ferred into the irradiated recipient mice, as previously
described.29 Bone marrow chimerization was detected after 8
weeks, and only mice with >90% chimerization were used.
Statistics
Data were analyzed with standard statistical analysis, that is,
one-way analysis of variance, Fisher’s post hoc test,
Neuman-Keuls multicomparison test for >2 groups, or
a Student’s t-test for only two groups of animals. All values
are reported as means  SEM with more than ﬁve mice per
group.
Results
Colonic Inﬂammation Is Associated with
IL-6eDependent Thrombocytosis and Appearance
of Immature Platelets
A well-characterized response to human IBD is thrombo-
cytosis.4,8,30 Figure 1A shows that DSS-induced colonic
inﬂammation in WT mice is also associated with a signiﬁcant
increase in total platelet count on day 6 of DSS treatment. This
response was accompanied by increases in the numbers of
immature (TOþ) and mature (TO) platelets (Figure 1, BeD).175
Senchenkova et alThese increases in total, immature, and mature platelets were
not detected in either IL-6/ mice or in IL-6/0WT bone
marrow chimeras, suggesting that IL-6 derived from cells of
myeloid origin mediates the thrombocytosis associated with
DSS-induced colitis. A role for IL-6 in mediating DSS-
induced thrombocytosis is also supported by the observation
(data not shown) that WT-DSS mice treated on day 5 with an
IL-6rb neutralizing antibody (936  163  103 platelets/mL),
but not an IL-6ra antibody (1368  94  103 platelets/mL),
resulted in a signiﬁcant reduction in platelet count on day 6 of
DSS, compared with untreated colitic (day 6) mice (1741 
215  103 platelets/mL).
IL-6eDependent Colitis-Induced Thrombocytosis Does
Not Result from a Prolongation of Platelet Life Span
The IL-6edependent increase in immature platelets in DSS
colitic mice is consistent with the known ability of this
cytokine to enhance platelet production.17 Because an
increased platelet count can also result from an extended
platelet life span, we also evaluated the inﬂuence of DSS-
induced colonic inﬂammation on the life span of mature
and immature platelets of both WT and IL-6/ mice. As
shown in Figure 2, A and B, the life span of immature
(23.10  0.8 hours) and mature (110  5.7 hours) platelets
in WT noncolitic (control) mice was not signiﬁcantly altered
by DSS treatment in WT, IL-6/, or IL-6/0WT mice.
Hyperreactivity of Platelets to Thrombin in DSS Colitic
Mice Is Mediated by IL-6
Platelets from patients with IBD are known to exhibit
a hypersensitivity to aggregation in response to different
agonists.31 This phenomenon is also evident in platelets176derived from mice with DSS colitis.14 Figure 3A shows the
large increase in platelet aggregation velocity observed in
platelet-rich plasma from DSS colitic WT mice after expo-
sure to an EC50 dose of thrombin. This 2.5-fold increase
(compared with WT controls) in platelet aggregation
velocity was not evident in platelet-rich plasma derived
from either IL-6/ or IL-6/0WT mice treated with
DSS, suggesting that IL-6 (derived from myeloid cells)
plays an important role in the altered platelet aggregation
response that accompanies DSS colitis.
To further evaluate the contribution of IL-6 to colitis-
induced platelet hyperaggregation, WT DSS colitic mice were
treated with a blocking antibody directed against either the a or
b (gp130) subunit of the IL-6 receptor (Figure 3B). The results
of these experiments indicated that immunoblockade of the
b-subunit of IL-6r completely prevented the exaggerated
aggregation response of platelets from colitic mice to
thrombin. Although blockade of the a-subunit (membrane-
bound) of IL-6r also reduced the aggregation response to
thrombin, this intervention was not as effective as b-subunit
blockade. Measurements of platelet count in arterial blood of
WT controls (992  60  103/mL), WT-DSS mice (1741 
215  103/mL), and mice treated with the IL-6r antibodies
indicated that the DSS-induced thrombocytosis was signiﬁ-
cantly blunted by treatment with the IL-6rb monoclonal anti-
body (936 163 103/mL; P< 0.01), but not with the IL-6ra
monoclonal antibody (1368  94  103/mL).
Administration of Murine IL-6 in WT Mice Promotes
Microvascular Thrombus Formation
Although some pro-inﬂammatory cytokines (eg, TNF-a,
IL-1b) have been shown to promote a microvascular throm-
bosis response similar to experimental colitis,14,15 theFigure 1 Platelet levels in control and DSS-fed
mice. Changes in blood levels of total platelets (A),
immature platelets (C), and mature platelets (D) in
mice placed on regular drinking water (WT-H2O) or
3% DSS. Representative ﬂow cytometric analyses of
mature (TO) and immature (TOþ) platelets in the
different experimental groups (WT-H2O, n Z 5;
WT-DSS, nZ 7; IL-6/-DSS, nZ 5; IL-6/0WT,
nZ 5) B: The platelet populations were gated on
CD41þ cells. WT, IL-6/, and IL-6/0WT mice
were studied. *P < 0.001 versus WT-H2O; **P <
0.01 versus WT-DSS; and ***P < 0.01 versus
WT-DSS.
ajp.amjpathol.org - The American Journal of Pathology
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Figure 2 Platelet life span. Life span determinations for immature
(TOþ) (A) and mature (TO) (B) biotinylated platelets in WT mice placed
on regular drinking water (WT-H2O, n Z 5) or 3% DSS in drinking water
(nZ 7). IL-6/-DSS (nZ 5) and IL-6/0WT (nZ 5) chimeras are also
shown. No differences were noted between experimental groups.
IL-6 and Colitis-Induced Thrombosisprothrombogenic effects of IL-6 have not been previously
assessed. Figure 4C shows that intrascrotal administration of
murine IL-6 induces a dose-dependent acceleration of light/
dye-induced thrombosis, as reﬂected by a reduced time to
ﬂow cessation (which is evident at all doses) and a shorter time
of onset of thrombus formation (evident only at the higher
dose).0
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Figure 3 Thrombin-induced platelet aggregation. A: Detection of
platelet aggregation velocity (in relative units) after exposure to an EC50 dose
(0.63 U/mL) of thrombin in WT mice on regular drinking water (WT-H2O,
n Z 7), WT-DSS (n Z 7), IL-6/-DSS (n Z 7), and IL-6/0WT-DSS
(nZ 6). ***P< 0.001 versus WT-H2O; **P< 0.01 versus WT-DSS. B: Platelet
aggregation velocity after thrombin exposure in WT-H2O (nZ 7), untreated
WT-DSS (n Z 7), and WT-DSS mice receiving a blocking antibody directed
against either the IL-6 receptor a (IL-6ra) (n Z 5) or b (IL-6rb) chain
(nZ 6). ***P< 0.001 versus WT-H2O; **P< 0.01 versus WT-DSS; *P< 0.05
versus WT-DSS.IL-6 Mediates the Accelerated Thrombus Development
Associated with DSS Colitis
The contribution of IL-6 to colitis-enhanced thrombus
development was evaluated with both immunoblockade and
genetic deletion strategies (Figure 4). A comparison of the
thrombosis responses in WT-DSS and IL-6/-DSS mice
indicated that IL-6 deﬁciency completely prevents the
reductions in both time of onset and time to ﬂow cessation
induced by DSS after light/dye injury (Figure 4A). Simi-
larly, immunoblockade of the IL-6 in colitic WT mice was
nearly as effective as IL-6 deﬁciency in reversing the colitis-
induced thrombosis response (Figure 4B).
IL-6edeﬁcient mice treated with DSS exhibited a small
yet signiﬁcant reduction in disease activity index and colon
weightelength ratio (Figure 5, AeC). Disease activity
index values for IL-6/0WT chimeras on DSS were
higher than WT-DSS on days 4 and 5, but signiﬁcantly
lower on day 6. However, no signiﬁcant differences were
noted between WT-DSS and IL-6edeﬁcient mice for total
histology score (Figure 5D). Similarly, no differences were
noted for the individual components of the total histological
score, that is, severity of inﬂammation, depth of injury, and
crypt damage.The American Journal of Pathology - ajp.amjpathol.orgDiscussion
Although it is generally appreciated that abnormalities in
both coagulation and platelet function may contribute to the
enhanced thrombus formation that is associated with IBD,
most attention has been focused on altered coagulation as
the underlying molecular basis for the thrombogenic
phenotype assumed by the vasculature in IBD.1,3 Less
attention has been devoted to the potential contribution of
platelets despite numerous reports that describe elevated
blood platelet levels and platelet hyperreactivity in both
human and experimental colitis.3,14 Previous studies from
our laboratory have indicated that the platelet abnormalities
and enhanced thrombus development described in human
IBD are recapitulated in both acute (DSS) and chronic (T-
cell transfer) models of experimental colitis. For example,
we have reported that DSS- and T-cell transfer-induced
colitis are accompanied by nearly identical changes in
thrombus development.14 More recently, we have reported
that the two distinct models of experimental colitis exhibit
nearly identical responses for thrombocytosis, appearance of
mature and immature platelets, increased number of acti-
vated circulating platelets, and increased number of plate-
leteleukocyte aggregates.32
Here, the DSS model was used to address the role of
altered platelet production and reactivity in the enhanced
thrombus development that accompanies colitis and177
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Figure 4 Light/dye-induced thrombus formation in cremaster arteri-
oles. Effects of IL-6/ (nZ 9) (A) and IL-6 immunoblocking (nZ 8) (B)
on light/dye-induced microvascular thrombosis in arterioles. *P < 0.05
versus WT-H2O (nZ 10); **P < 0.01 versus WT-DSS (nZ 10); yP < 0.05
versus WT-DSS. Effects of intrascrotal administration of IL-6 (10, 100, or
1000 ng/mouse; nZ 5 for each one) dissolved in 0.2 mL of normal saline
on thrombus formation (5 hours after injection) in cremaster muscle
arterioles (C). *P < 0.05 versus sham-operated mice (n Z 7).
Senchenkova et alspeciﬁcally examined the role of IL-6, a cytokine that has
been implicated in IBD pathogenesis,33 as a gut-derived
factor that targets the production and reactivity of plate-
lets, ultimately resulting in enhanced thrombus develop-
ment. Our ﬁndings implicate IL-6 as a major factor
underlying the accelerated microvascular thrombosis
detected in extra-intestinal tissue during experimental IBD
and lend support to the possibility that increased platelet
production and enhanced platelet reactivity are important
targets of IL-6 action that predispose the vasculature to
thrombus development during colonic inﬂammation.
IBD is often accompanied by an increased blood platelet
count (reactive thrombocytosis), with 50% to 100%
increases in platelet count commonly reported for patients
with active IBD, compared with control subjects.6,7,34 The
association of thrombocytosis with active IBD has led to the
proposal that platelet count may be a useful marker of
disease activity.4,8 Our study has indicated that the colonic
inﬂammation induced by DSS administration in mice results
in an increased platelet count (50% to 100%) that is
comparable with that noted in patients with IBD. The results
of this study also provide two lines of evidence to suggest178that the increased platelet count induced by DSS results
from increased platelet production. First, we detected
a signiﬁcant increase in the number of circulating immature
(TO staining) platelets. Second, no change in platelet life
span was noted when the DSS-treated WT mice were
compared with WT mice on regular drinking water. The
latter observation is consistent with a clinical report that
described a normal life span of platelets labeled with
indium-111 in patients with active IBD.7
IL-6 has been shown to act on the maturation stages of
megakaryocytosis to stimulate platelet production in
mice17,35 and other species.35,36 The cytokine is also able to
indirectly stimulate platelet production by enhancing hepatic
output of TPO, a potent thrombopoeitic agent that also
targets the megakaryocyte.37 Our ﬁnding that IL-6 deﬁ-
ciency largely prevented the thrombocytosis and appearance
of immature platelets without affecting platelet life span in
DSS-treated mice provides strong evidence that IL-6 is
largely responsible for the increased platelet production that
is elicited by experimental colitis. Furthermore, our obser-
vation that immunoblockade of the b-subunit (gp130), but
not the membrane bound a-subunit, of the IL-6 receptor
blunts the DSS-induced thrombocytosis, as previously
described in IL-6einfused dogs treated with anti-gp130,38
suggests that IL-6 stimulates its receptors on the megakar-
yocyte by binding to the circulating soluble isoform of the
IL-6 receptor, which then engages with gp130 to initiate
a trans-signaling mechanism that results in increased
platelet production.38e42
Another characteristic feature of the altered platelet
function in IBD is hyperreactivity to agonist stimulation.7,32
Platelets from patients with IBD exhibit an exaggerated
aggregation response to stimulation by agonists such ADPajp.amjpathol.org - The American Journal of Pathology
IL-6 and Colitis-Induced Thrombosisand collagen.7,32 Our focus on thrombin is based on the
critical role of this prothrombotic agent in mediating the
enhanced extra-intestinal thrombosis that accompanies
colonic inﬂammation in the DSS model.43 However, the
present study extends our previous work on colitis-induced
alterations in platelet function by implicating IL-6 as
a mediator of the platelet hyperreactivity that accompanies
DSS-induced colonic inﬂammation.19 We show that the
exaggerated platelet aggregation response to the EC50 dose
of thrombin in DSS-treated mice is not observed in either
IL-6/ or IL-6/0WT mice. Similarly, we noted that
immunoblockade of either the a- or b-subunit of IL-6r
blunts the response, with gp130 blockade providing
complete protection, whereas the a-subunit (that targets the
membrane bound form) is only partially protective. The
latter observation suggests that both membrane-associated
and soluble IL-6r participate in the IL-6edependent
platelet hyperreactivity in DSS colitis. Although the
contribution of TPO to the altered platelet reactivity remains
unclear, previous work has shown that the infusion of TPO
in dogs does not alter platelet responses to thrombin,44
which differs from the increased platelet reactivity to
thrombin noted after IL-6 infusion.19,44
IL-6 may mediate its effects on platelet reactivity by
either acting directly on platelets and via stimulation of
thrombopoiesis.44 Reports describe IL-6einduced activa-
tion of human platelets when the cytokine is incubated with
platelet-rich plasma.45e47 By contrast, although dogs treated
with IL-6 exhibit platelet hyperreactivity,18,19,44 direct
ex vivo incubation of dog platelets with IL-6 does not alter
platelet activation,19,44 suggesting that the cytokine is indi-
rectly enhancing platelet reactivity in vivo. The latter
observation has led to the proposal that increased IL-6 levels
are more likely to alter platelet reactivity via an action on
hematopoietic tissue.18,48 Because young (immature) plate-
lets are considered to be more reactive to agonist stimula-
tion,10,18,44 it follows that stimulants of thrombopoiesis
(such as IL-6) would increase the percentage of circulating
platelets that are immature and hyperreactive,44 thereby
resulting in a phenotypic change in the reactivity of the total
platelet population.
Our study also provides several lines of evidence that
implicates IL-6 as a mediator of the accelerated light/dye
injury-induced thrombosis observed in cremaster muscle
arterioles of DSS-treated mice. First, we present the novel
observation that exogenous IL-6 elicits a dose-dependent
acceleration of thrombus development in arterioles of WT
mice (without colitis). Second, we show that immuno-
blockade of IL-6 affords signiﬁcant protection against DSS-
induced thrombogenesis. Finally, mice that are genetically
deﬁcient in IL-6 exhibit complete protection against colitis-
enhanced thrombus formation. Although we do not provide
deﬁnitive evidence on the mechanisms that underlie the
ability of IL-6 to mediate the enhanced thrombosis associ-
ated with colitis, it is tempting to speculate that the accel-
erated IL-6edependent thrombosis is a direct reﬂection ofThe American Journal of Pathology - ajp.amjpathol.orgthe proposed actions of the cytokine on platelet production
and reactivity in colitic mice. Such a connection has been
reported in a zebra ﬁsh model of arterial thrombosis,
wherein it was shown that young, hyperreactive thrombo-
cytes initiate thrombus formation by rapidly accumulating at
the site of vessel damage, releasing agonists that recruit
more young thrombocytes, and then recruiting more mature
(less reactive) thrombocytes into the growing thrombus.49
Consideration should be given to the known effects of
IL-6 on the coagulation system. For example, IL-6 stimu-
lates coagulation in humans as reﬂected in increased
thrombin-antithrombin III complexes and elevated levels of
prothrombin activation of fragment F1 and F2.50 Elimina-
tion of IL-6 attenuates the activation of coagulation.38,51
IL-6 is also known to enhance the production of other
cytokines, such as TNF-a and IL-1b, which can also
inﬂuence the coagulation system and promote thrombus
formation. TNF-a and IL-1b are also known to stimulate
IL-6 production via an NF-kBedependent mechanism. This
tight interdependence of IL-6 with TNF-a and IL-1b likely
explains why TNF-a and IL-1b have also been shown to
contribute to DSS colitis-enhanced thrombus formation.41,52
Although the hierarchy of IL-6, TNF-a, and IL-1b as
mediators of the abnormal platelet function and enhanced
thrombus development in colitis remains unclear, the
available evidence points to a dominant role for IL-6. For
example, we have previously reported that individual
immunoblockade of TNF-a and IL-1b affords only partial
protection against colitis-accelerated thrombus formation,
whereas simultaneous blockade of both cytokines affords
complete protection similar to IL-6 immunoblockade
alone.14,15 Similarly, although the exaggerated thrombin-
induced platelet aggregation response to DSS is absent in
IL-6edeﬁcient mice (Figure 3), IL-1b deﬁciency affords no
protection.14
The role of IL-6 in mediating the colonic inﬂammation
that is elicited by DSS treatment is another important
consideration. Previous studies in murine models of colitis
have reported an attenuation of macroscopic (disease
activity index, colon weightelength ratio) and microscopic
(histopathology) indices of colonic inﬂammation and
disease activity with IL-6 deﬁciency.53e55 However, the
ﬁndings of our study indicate that IL-6 deﬁciency confers
moderate protection against DSS-induced loss of body
weight and colonic thickening, without improving the
degree of colonic inﬂammation or damage (Figure 5). These
observations lessen the likelihood that IL-6 deﬁciency
blunts the platelet abnormalities and enhanced extra-
intestinal thrombosis indirectly by limiting the intensity of
the colonic inﬂammation. Further support for a more direct
action of IL-6 on the thrombogenic responses is evidenced
by our observation (Figure 3B) that immunoblockade of
IL-6 on day 5 of DSS treatment, when inﬂammation was
already well established, resulted in a signiﬁcant attenuation
of the exaggerated thrombin-mediated platelet aggregation
response normally observed on day 6 of DSS treatment.179
Senchenkova et alIn conclusion, the ﬁndings of this study provide evidence
to implicate IL-6 as a mediator of the thrombocytosis,
platelet hyperreactivity, and enhanced thrombus develop-
ment that are associated with experimental colitis. The IL-
6edependent increase in blood platelet count elicited during
DSS-induced colonic inﬂammation appears to result from an
enhancement of platelet production, rather than a prolonga-
tion of platelet life span. The appearance of immature
platelets during colitis supports the view that enhanced
thrombus development in extra-intestinal tissues results
from an increased percentage of young, hemostatically
active platelets that more readily aggregate in blood and
accumulate at an accelerated rate at sites of vessel injury.Acknowledgments
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